evERA Breast Cancer
373 patients with ER+/HER2− advanced disease after CDK4/6 inhibitor and endocrine therapy.
Treatment and comparator
Giredestrant + everolimus vs standard endocrine therapy + everolimus.
Reported outcomes
Median PFS 8.8 vs 5.5 months; HR 0.56 (95% CI 0.44–0.71; P<0.001). ESR1-mutated subgroup: 10.0 vs 5.5 months; HR 0.38.
Harms and treatment burden
Grade 3–4 adverse events 51.1% vs 37.1%; discontinuation 17.0% vs 11.8%; OS immature.
NNT is not derived from median survival or hazard ratios. Use only source-reported fixed-time absolute rates. No unreported QoL values are imputed.
Interpretation and limitations
Distinguish superiority, non-inferiority and a non-significant result. Interpret subgroup analyses in light of prespecification, multiplicity and interaction tests. This page separates historical trial results from current practice; full clinical freshness review and browser-rendered visualization QA remain pending.
Primary source / registry
Current-practice context: check subsequent follow-up and contemporary disease-specific guidelines before applying these results.